Source: Medicines & Healthcare Products Regulatory Agency (GB) Revision Year: 2019 Publisher: CHEPLAPHARM Arzneimittel GmbH, Ziegelhof 24, 17489, Greifswald, Germany
VEPESID 50 mg capsule, soft.
| Pharmaceutical Form |
|---|
|
Capsule, Soft. Opaque pink. |
Each capsule contains 50 mg etoposide.
Excipients with known effect:
Each 50 mg capsule, soft contains:
For the full list of excipients, see section 6.1.
| Active Ingredient | Description | |
|---|---|---|
| Etoposide |
The main effect of etoposide appears to be at the late S and early G2 portion of the cell cycle in mammalian cells. The predominant macromolecular effect of etoposide seems to be the rupture of the double strand by an interaction with DNA-topoisomerase II or by the formation of free radicals. Etoposide has been shown to cause metaphase arrest in chick fibroblasts. |
| List of Excipients |
|---|
|
Capsule content: Citric acid, anhydrous (E330) Capsule shell: Glycerol (85 per cent) (E422) |
Pack of 20, 50 Capsules, softgels.
Not all pack sizes may be marketed.
CHEPLAPHARM Arzneimittel GmbH, Ziegelhof 24, 17489, Greifswald, Germany
PL 27041/0016
29 April 1983 / 18 September 2002
| Drug | Countries | |
|---|---|---|
| VEPESID | Austria, Australia, Canada, Estonia, Spain, Finland, Ireland, Japan, Malta, Netherlands, New Zealand, Romania, United Kingdom |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
